Antimalarials

• 

  Subject Areas on Research

  • 1,2,4-Trioxanes as potential antimalarial agents. 
  • A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy. 
  • A Systematic Analysis of Mosquito-Microbiome Biosynthetic Gene Clusters Reveals Antimalarial Siderophores that Reduce Mosquito Reproduction Capacity. 
  • A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo. 
  • Absence of Association Between Sickle Trait Hemoglobin and Placental Malaria Outcomes. 
  • Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. 
  • Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. 
  • An innovative pay-for-performance (P4P) strategy for improving malaria management in rural Kenya: protocol for a cluster randomized controlled trial. 
  • Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. 
  • Antibiotic and antimalarial quinones from fungus-growing ant-associated Pseudonocardia sp. 
  • Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms. 
  • Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Retain High Efficacy for Treatment of Uncomplicated Plasmodium falciparum Malaria in Myanmar. 
  • Artemisinin resistance in Plasmodium falciparum malaria. 
  • Body temperature is a poor predictor of malaria parasitaemia in children with acute diarrhoea. 
  • Bull's-eye maculopathy associated with quinacrine therapy for malaria. 
  • Characterization of Plasmodium liver stage inhibition by halofuginone. 
  • Chemical interrogation of the malaria kinome. 
  • Chloroquine resistance of Plasmodium falciparum is associated with severity of disease in Nigerian children. 
  • Chloroquine, quinine and quinidine inhibit calcium release from macrophage intracellular stores by blocking inositol 1,4,5-trisphosphate binding to its receptor. 
  • Comparative efficacy of intramuscular artemether and intravenous quinine in Nigerian children with cerebral malaria. 
  • Current therapies and future possibilities for drug development against liver-stage malaria. 
  • Deorphaning pyrrolopyrazines as potent multi-target antimalarial agents. 
  • Dihydroquinazolinone inhibitors of proliferation of blood and liver stage malaria parasites. 
  • Discovery of Dual-Stage Malaria Inhibitors with New Targets. 
  • Discovery of novel targets of quinoline drugs in the human purine binding proteome. 
  • Discovery of potent Plasmodium falciparum protein kinase 6 (PfPK6) inhibitors with a type II inhibitor pharmacophore. 
  • Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. 
  • Does anti-malarial drug knowledge predict anti-malarial dispensing practice in drug outlets? A survey of medicine retailers in western Kenya. 
  • Does improving appropriate use of malaria medicines change population beliefs in testing and treatment? Evidence from a randomized controlled trial. 
  • Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. 
  • Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali. 
  • Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. 
  • Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. 
  • Evaluating Response Time in Zanzibar's Malaria Elimination Case-Based Surveillance-Response System. 
  • Evaluation of in-hospital management for febrile illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the treatment of malaria. 
  • Factors influencing malaria control policy-making in Kenya, Uganda and Tanzania 
  • Genetic Evidence of Importation of Drug-Resistant Plasmodium falciparum to Guatemala from the Democratic Republic of the Congo. 
  • Gilding the Lily? Enhancing Antenatal Malaria Prevention in HIV-Infected Women. 
  • Health agencies end in-fighting on malaria. 
  • How do malaria testing and treatment subsidies affect drug shop client expenditures? A cross-sectional analysis in Western Kenya. 
  • Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. 
  • Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. 
  • Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. 
  • Identification of Novel 2,4,5-Trisubstituted Pyrimidines as Potent Dual Inhibitors of Plasmodial Pf GSK3/Pf PK6 with Activity against Blood Stage Parasites In Vitro. 
  • Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. 
  • Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. 
  • Improving rational use of ACTs through diagnosis-dependent subsidies: Evidence from a cluster-randomized controlled trial in western Kenya. 
  • In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors. 
  • Incentivizing appropriate malaria case management in the private sector: a study protocol for two linked cluster randomized controlled trials to evaluate provider- and client-focused interventions in western Kenya and Lagos, Nigeria. 
  • Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria. 
  • Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, eastern Africa. 
  • Inhibition of endothelial activation: a new way to treat cerebral malaria? 
  • Innovative public-private partnership to target subsidised antimalarials: a study protocol for a cluster randomised controlled trial to evaluate a community intervention in Western Kenya. 
  • Intermittent preventive malaria treatment in Tanzanian infants. 
  • Intermittent preventive treatment for malaria in infants: moving forward, cautiously. 
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. 
  • It's about Time: Insights into the Modes of Action of Antimalarials. 
  • Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. 
  • Lack of association between falciparum malaria parasitemia and acute diarrhea in Nigerian children. 
  • Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. 
  • Malaria researchers say global fund is buying "useless drug". 
  • Malaria: a rising incidence in the United States. 
  • Minimal Impact by Antenatal Subpatent Plasmodium falciparum Infections on Delivery Outcomes in Malawian Women: A Cohort Study. 
  • Modelling the incremental benefit of introducing malaria screening strategies to antenatal care in Africa. 
  • Molecular assays for antimalarial drug resistance surveillance: A target product profile. 
  • Molecular surveillance for drug-resistant Plasmodium falciparum in clinical and subclinical populations from three border regions of Burma/Myanmar: cross-sectional data and a systematic review of resistance studies. 
  • Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. 
  • Novel Synthetic Polyamines Have Potent Antimalarial Activities in vitro and in vivo by Decreasing Intracellular Spermidine and Spermine Concentrations. 
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons. 
  • Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate. 
  • Paired-ion liquid chromatographic method for the analysis of a phenanthrenemethanol antimalarial in whole blood. 
  • Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study. 
  • Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. 
  • Piloting the Affordable Medicines Facility-malaria: what will success look like? 
  • Plasmodium PK9 Inhibitors Promote Growth of Liver-Stage Parasites. 
  • Plasmodium falciparum sulfadoxine resistance is geographically and genetically clustered within the DR Congo. 
  • Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey? 
  • Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes. 
  • Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. 
  • Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. 
  • Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo. 
  • Random Forest Model Predictions Afford Dual-Stage Antimalarial Agents. 
  • Rapid increases in parasitemia following red cell exchange for malaria. 
  • Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. 
  • Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. 
  • Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial. 
  • Socio-economic status and malaria-related outcomes in Mvomero District, Tanzania. 
  • Strain theory of malaria: the first 50 years. 
  • Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. 
  • Subsidise the test, the treatment or both? Results of an individually randomised controlled trial of the management of suspected malaria fevers in the retail sector in western Kenya. 
  • Subsidising artemisinin-based combination therapy in the private retail sector. 
  • Systemic lupus erythematosus. 
  • Tafenoquine: A Step toward Malaria Elimination. 
  • The association between price, competition, and demand factors on private sector anti-malarial stocking and sales in western Kenya: considerations for the AMFm subsidy. 
  • The changing landscape of Plasmodium falciparum drug resistance in the Democratic Republic of Congo. 
  • The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. 
  • The next opportunity in anti-malaria drug discovery: the liver stage. 
  • The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). 
  • Therapeutic approaches to the treatment of rheumatoid disease. 
  • Time for a "Third Wave" of malaria activism to tackle the drug stock-out crisis. 
  • Treatment of erythrocytes with the 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of Plasmodium falciparum and enhances parasite sensitivity to chloroquine. 
  • Trends in fever case management for febrile inpatients in a low malaria incidence setting of Tanzania. 
  • WHO urges Africa to use more effective malaria medicines. 
  • [Epidemiology of chemoresistant Plasmodium falciparum]. 
  • [LMP-420, a new therapeutic approach for cerebral malaria?]. 
• 

  Keywords of People

  • O'Meara, Wendy P, Associate Professor of Medicine, Medicine, Infectious Diseases